Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) was downgraded by equities researchers at Roth Capital from a “buy” rating to a “neutral” rating in a report released on Tuesday, FinViz reports. They presently have a $0.75 price target on the stock, down from their previous price target of $3.00. Roth Capital‘s target price indicates a potential upside of 1.35% from the stock’s previous close.
Several other analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, October 15th. JPMorgan Chase & Co. set a $0.75 target price on Rapid Micro Biosystems in a report on Tuesday. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $1.81.
Read Our Latest Analysis on RPID
Rapid Micro Biosystems Stock Up 13.7%
RPID stock opened at $0.74 on Tuesday. The firm has a market cap of $37.12 million, a PE ratio of -0.66 and a beta of 1.52. Rapid Micro Biosystems has a 1 year low of $0.58 and a 1 year high of $4.94. The company has a fifty day simple moving average of $0.91 and a 200 day simple moving average of $2.06. The company has a current ratio of 2.55, a quick ratio of 1.51 and a debt-to-equity ratio of 1.08.
Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.01). Rapid Micro Biosystems had a negative return on equity of 177.04% and a negative net margin of 145.56%. The business had revenue of $9.53 million for the quarter, compared to analyst estimates of $9.85 million. Sell-side analysts anticipate that Rapid Micro Biosystems will post -0.94 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its holdings in Rapid Micro Biosystems by 9.5% in the 1st quarter. Renaissance Technologies LLC now owns 126,617 shares of the company’s stock worth $287,000 after acquiring an additional 10,990 shares during the period. Bank of America Corp DE lifted its position in Rapid Micro Biosystems by 139.9% during the 1st quarter. Bank of America Corp DE now owns 31,014 shares of the company’s stock worth $70,000 after acquiring an additional 18,085 shares during the last quarter. Temasek Holdings Private Ltd bought a new stake in Rapid Micro Biosystems during the first quarter valued at about $50,000. Dimensional Fund Advisors LP boosted its holdings in Rapid Micro Biosystems by 55.9% during the first quarter. Dimensional Fund Advisors LP now owns 87,589 shares of the company’s stock valued at $199,000 after acquiring an additional 31,407 shares during the period. Finally, Pekin Hardy Strauss Inc. bought a new stake in Rapid Micro Biosystems during the third quarter valued at about $41,000. 52.60% of the stock is currently owned by institutional investors and hedge funds.
Recent Rapid Micro Biosystems Headlines
Here are a few of the latest headlines about RPID:
- Positive Sentiment: Merck KGaA signed a definitive agreement to acquire all outstanding RPID shares for $0.75 each in cash. Merck said Rapid Micro’s Growth Direct platform would strengthen its pharmaceutical quality-control workflow offerings. Acquisition announcement
- Neutral Sentiment: Law firms announced investigations into whether the $0.75 offer fairly values RPID and whether deal terms could limit competing offers. These are inquiries, not findings, but could add uncertainty around the transaction. Shareholder investigation report
- Negative Sentiment: Third-quarter results were slightly below analyst expectations: RPID reported a $0.22-per-share loss versus estimates of $0.21, and revenue of $9.53 million versus estimates of $9.85 million. The company also filed a notification of late quarterly filing, adding a reporting concern. Third-quarter results Late filing report
Rapid Micro Biosystems Company Profile
Rapid Micro Biosystems develops automated microbial detection systems for pharmaceutical, biotechnology and other life sciences manufacturers. Its products are designed to support quality-control testing by identifying and measuring microbial growth in manufacturing environments and products. The company’s Growth Direct platform combines laboratory instruments, consumables and software to automate microbial testing. Its applications include sterility testing, bioburden testing and environmental monitoring, helping manufacturers assess contamination during production.
Read More
- Five stocks we like better than Rapid Micro Biosystems
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
